Biotech | April 13, 2022
Novel Covid-19 vaccine may protect the immunocompromised
The peptide-based vaccine induces a t cell-dependent response
The peptide-based vaccine induces a t cell-dependent response
New Covid-19 Medriva Rapid Antigen Test kits with very high- sensitivity now available in Australia
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Sputnik Light is the first component of Sputnik V
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and Delta
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package)
Subscribe To Our Newsletter & Stay Updated
